J Clin Neurol.  2007 Mar;3(1):24-30. 10.3988/jcn.2007.3.1.24.

Genetic Contribution of Catechol-O-methyltransferase Polymorphism in Patients with Migraine without Aura

• Park JW
• Lee KS
• Kim JS
• Kim YI
• Shin HE

• KMID: 1700683
• DOI: http://doi.org/10.3988/jcn.2007.3.1.24

Abstract

BACKGROUND
Recent genetic association studies have investigated the possible genetic role of the dopaminergic system in migraine. Catechol-O-methyltransferase (COMT) is an enzyme that plays a crucial role in the metabolism of dopamine and its genetic polymorphism is associated with three- to fourfold variation of enzymatic activity.
OBJECTIVES
The objective of this study was to elucidate the role of the COMT polymorphism in the genetic susceptibility to migraine and its phenotypic expression in patients with migraine without aura (MWOA).
METHODS
Ninety-seven patients with MWOA and 94 healthy volunteers were included in the study. After amplifying COMT genes by the polymerase chain reaction, we assessed their genotype frequencies and allele distributions by based on restriction fragment length polymorphisms. We classified all MWOA patients into two groups according to their COMT genotype: with the L allele (N = 43), and without this allele (N = 54).
RESULTS
The genotype frequency and allele distribution of the COMT polymorphism did not differ between MWOA patients and the control group. During migraine attacks, MWOA patients with the L allele showed a higher pain intensity of headache (P = 0.001) and a higher incidence of the accompanying nausea/vomiting (94% vs 75%; P = 0.026) compared with MWOA patients without the L allele.
CONCLUSIONS
Although the COMT polymorphism does not appear to be involved in predisposition to the development of MWOA, this genetic factor could be involved in the phenotypic expression of MWOA.

Keyword

Catechol-O-methyltransferase; Migraine without aura; Polymorphism; Dopamine

MeSH Terms

Alleles
Catechol O-Methyltransferase*
Dopamine
Genetic Association Studies
Genetic Predisposition to Disease
Genotype
Headache
Healthy Volunteers
Humans
Incidence
Metabolism
Migraine Disorders*
Migraine without Aura*
Polymerase Chain Reaction
Polymorphism, Genetic
Polymorphism, Restriction Fragment Length
Catechol O-Methyltransferase
Dopamine

Reference

1. Fanciullacci M, Michelacci S, Curradi C, Sicuteri F. Hyperresponsiveness of migraine patients to the hypotensive action of bromocriptine. Headache. 1980. 20:99–102.

2. Geraud G, Guell A, Courtade M, Dupui P, Bes A. Clinical value of a dopaminergic agonist administration in migraine patients. Headache. 1983. 23:191–192.

3. Montastruc JL, David J, Rascol A. Does the piribedil test permit predicting the efficacy of domperidone, a dopaminergic antagonist, in the treatment of migraine? Headache. 1985. 25:332–333.

4. Bes A, Dupui P, Guell A, Bessoles G, Geraud G. Pharmacological exploration of dopamine hypersensitivity in migraine patients. Int J Clin Pharmacol Res. 1986. 6:189–192.

5. van Hilten JJ. The migraine - dopamine link: do migraine and Parkinson's disease coexist? Clin Neurol Neurosurg. 1992. 94:Suppl. S168–S170.

6. Nagel-Leiby S, Welch KMA, D'Andrea G, Grunfeld S, Brown E. Event-related slow potentials and associated catecholamine function in migraine. Cephalalgia. 1990. 10:317–329.

7. Fisher H. A new approach to emergency department therapy of migraine headache with intravenous haloperidol: a case series. J Emerg Med. 1995. 13:119–122.

8. Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, Cragg S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther. 1999. 84:133–156.

9. Mascia A, Afra J, Schoenen J. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia. 1998. 18:174–182.

10. Cerbo R, Barbanti P, Buzzi MG, Fabbrini G, Brusa L, Roberti C, et al. Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin Neuropharmacol. 1997. 20:36–41.

11. Sicuteri F. Dopamine, the second putative protagonist in headache. Headache. 1977. 17:129–131.

12. Honkasalo ML, Kaprio J, Winter T, Heikkila K, Sillanpaa M, Koskenvuo M. Migraine and concomitant symptoms among 8167 adult twin pairs. Headache. 1995. 35:70–78.

13. Larsson B, Bille B, Pedersen NL. Genetic influence in headaches: a Swedish twin study. Headache. 1995. 35:513–519.

14. Russell MB, Olesen J. The genetics of migraine without aura and migraine with aura. Cephalalgia. 1993. 13:245–248.

15. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, Goldberg R, Kucherlapati R, Papolos DF. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet. 1996. 67:468–472.

16. Strous RD, Bark N, Woerner M, Lachman HM. Lack of association of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia. Biol Psychiatry. 1997. 41:493–495.

17. Syvanen AC, Tilgmann C, Rinne J, Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics. 1997. 7:65–71.

18. Daniels JK, Williams NM, Williams J, Jones LA, Cardno AG, Murphy KC, et al. No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol-O-methyltransferase activity. Am J Psychiatry. 1996. 153:268–270.

19. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996. 6:243–250.

20. Papolos DF, Veit S, Faedda GL, Saito T, Lachman HM. Ultra-ultra rapid cycling bipolar disorder is associated with the low activity catechol-O-methyltransferase allele. Mol Psychiatry. 1998. 3:346–349.

21. Ermin Erdal M, Herken H, Yilmaz M, Bayazit YA. Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res. 2001. 94:193–196.

22. Headache classification subcommittee of the international headache society. The international classification of headache disorders. 2^nd Edn. Cephalalagia. 2004. 24:Suppl. 1–160.

23. Peroutka SJ. Dopamine and migraine. Neurology. 1997. 49:650–656.

24. Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997. 49:201–206.

25. Del Zompo M, Cherchi A, Palmas MA, Ponti M, Bocchetta A, Gessa GL, et al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology. 1998. 51:781–786.

26. Dichgans M, Forderreuther S, Deiterich M, Pfaffenrath V, Gasser T. The D2 receptor NcoI allele: absence of allelic association with migraine with aura. Neurology. 1998. 51:928.

27. Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR. Evidence for allelic association of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics. 2000. 3:35–40.

28. Shepherd AG, Lea RA, Hutchins C, Jordan KL, Brimage PJ, Griffiths LR. Dopamine receptor genes and migraine with and without aura: an association study. Headache. 2002. 42:346–351.

29. Mochi M, Cevoli S, Cortelli P, Pierangeli G, Soriani S, Scapoli C, et al. A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-beta-hydroxylase genes. Neurol Sci. 2003. 23:301–305.

30. Filic V, Vladic A, Stefulj J, Cicin-Sain L, Balija M, Sucic Z, Jernej B. Monoamine oxidases A and B gene polymorphisms in migraine patients. J Neurol Sci. 2005. 15:149–153.

31. Marziniak M, Mossner R, Benninghoff J, Syagailo YV, Lesch KP, Sommer C. Association analysis of the functional monoamine oxidase A gene promotor polymorphism in migraine. J Neural Transm. 2004. 111:603–609.

32. Tiihonen J, Hallikainen T, Lachman H, Saito T, Volavka J, Kauhanen J, et al. Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Mol Psychiatry. 1999. 4:286–289.

33. Kauhanen J, Hallikainen T, Tuomainen TP, Koulu M, Karvonen MK, Salonen JT, et al. Association between the functional polymorphism of catechol-O-methyltransferase gene and alcohol consumption among social drinkers. Alcohol Clin Exp Res. 2000. 24:135–159.

34. Hallikainen T, Lachman H, Saito T, Volavka J, Kauhanen J, Salonen JT, et al. Lack of association between thefunctional variant of the catechol-O-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior. Am J Med Genet. 2000. 96:348–352.

35. Ishiguro H, Haruo Shibuya T, Toru M, Saito T, Arinami T. Association study between high and low activity polymorphism of catechol-O-methyltransferase gene and alcoholism. Psychiatr Genet. 1999. 9:135–138.

36. Nakamura A, Inada T, Kitao Y, Katayama Y. Association between catechol-O-methyltransferase (COMT) polymorphism and severe alcoholic withdrawal symptoms in male Japanese alcoholics. Addict Biol. 2001. 6:233–238.

37. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain. 1995. 60:3–38.

38. Paalzow GH. L-dopa induces opposing effects on pain in intact rats: (-)-sulpiride, SCH 23390 or alpha-methyl-DL-p-tyrosine methylester hydrochloride reveals profound hyperalgesia in large antinociceptive doses. J Pharmacol Exp Ther. 1992. 263:470–479.

39. Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson's disease. Lancet. 1986. 1:1366–1369.

40. Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS. Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial. Neurology. 2003. 60:315–321.

41. Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. Headache. 1997. 37:377–382.

42. Hyde TM, Knable MB, Murray AM. Distribution of dopamine D1-D4 receptor subtypes in human dorsal vagal complex. Synapse. 1996. 24:224–232.

43. Kohli JD, Glock D, Goldberg LI. Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol. 1983. 89:137–141.

44. Sicuteri F, Bonucci M, Cangi F, Pietrini U, Fanciullacci M. Carroll JD, Pfaffenrath V, Sjaastad O, editors. Syncope and dopamine receptor hyperreactivity: myth and facts about basilar artery migraine. Migraine and Beta Blockade. 1985. Molndal: Hassle;147–160.